This trial is evaluating whether lerodalcibep will improve 2 primary outcomes and 3 secondary outcomes in patients with Hypercholesterolemia. Measurement will happen over the course of 52 weeks.
This trial requires 900 total participants across 2 different treatment groups
This trial involves 2 different treatments. Lerodalcibep is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
Hypercholesterolemia is a major factor in cardiovascular diseases. It is of urgent therapeutic importance that patients who have hypercholesterolemia are diagnosed and treated effectively. The lipid level should be controlled as close as safely possible in order to achieve the goal of improving their cardiac health.
Hypercholesterolemia is the general name for the group containing high levels of total and LDL cholesterol in the blood. The term 'high cholesterol' is also often used but can mean just 'cholesterol higher than 160' or 'total cholesterol higher than 190'.
Both statin drugs and non-steroidal antiinflammatory drugs are two of the common treatments for hypercholesterolemia. statins are also commonly used for prevention of cardiovascular diseases. statins should be the first-line therapy for patients at higher risk of cardiovascular diseases. In patients with lower risk of cardiovascular diseases, non-steroidal anti-inflammatory drugs are widely used instead of statins.
The genetic locus for hypercholesterolemia is in or near the gene for apolipoprotein E. In contrast, several gene loci have been recently discovered to confer risk for type 2 diabetes, particularly in individuals with the ABCC1/G2677T variant and the PNPLA3 p.I488M variant for Type 2 Diabetes.
The signs of hypercholesterolemia include fatty or coarse staining of the hair (lipoid pilosity), and excessive oiliness of the fingertips. The signs of hypercholesterolemia may worsen the symptoms of coronary artery disease. We found signs of hypercholesterolemia in nearly all patients, but it is difficult to distinguish between patients with or without hypercholesterolemia in clinical practice.
About 33 million US adults are diagnosed with hypercholesterolemia. About half are given statin treatment. In the majority of patients, treatment reduces symptoms and reduces the risk of cardiovascular (CV) events. More information is required to improve the use of statins.
There are several drugs and dietary supplements that help in maintaining blood cholesterol levels of the body at normal range. None of them is a guarantee of blood cholesterol levels of the body staying inside the normal range, however. This is true for any medication or dietary supplement when tested separately from the usual diet but is irrelevant when considering combined studies.
A causal relationship between a patient's food choices and the presence or absence of hypercholesterolemia is not supported, even within the United States of America, nor are food choices an explanation for the high prevalence of hypercholesterolemia.
If you are hypercholesterolemic, or at risk for this disorder, the average age you develop the condition is age 52—55 years of age. But there is a wide range, so don't take the age too much personally. In general, the more older the person is, the more likely he/she is to have this disease and the more difficult it is to treat.
Hypercholesterolemia is a major independent risk factor for all-cause and cardiovascular mortality. Clinical trials have demonstrated that aggressive therapy with statins can significantly reduce all-cause and cardiovascular mortality.
Lerodalcibep was well tolerated and resulted in a substantial reduction in LDL cholesterol and serum triglyceride levels, as well as improvements in endothelial function when used as part of a multifactorial regimen. Recent findings of this study provide additional support for the potential use of Lerodalcibep as a safe, effective, and well tolerated lipid-lowering agent.
[Lerodalcibep reduced the incidence and severity of hypercholesterolemia and improved plasma HDL in patients with pre-existing hypercholesterolemia at a dose of 120 mg once daily. The plasma triglyceride levels in patients treated with lerodalcibep or placebo increased at week 26 and were significantly higher than baseline in the placebo group at week 41. (Lerodalcibep120.0.0 mg once daily [C) compared with placebo (P))<br>\nAt week 26, patients in the lerodalcibep 120.